PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.92%
Negative revenue growth while ON stands at 1.24%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-2.87%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-1.68%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-1.68%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-2.71%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.18%
Share reduction while ON is at 6.43%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-3.45%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
25.02%
Dividend growth under 50% of ON's 196.32%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
-7.05%
Negative OCF growth while ON is at 1.83%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-9.93%
Negative FCF growth while ON is at 8.20%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
66.42%
10Y CAGR of 66.42% while ON is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
96.86%
Positive 5Y CAGR while ON is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
41.72%
3Y revenue/share CAGR above 1.5x ON's 9.35%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
241.13%
OCF/share CAGR of 241.13% while ON is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
127.23%
Below 50% of ON's 680.16%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
37.02%
3Y OCF/share CAGR under 50% of ON's 205.93%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
401.02%
10Y net income/share CAGR of 401.02% while ON is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
252.29%
5Y net income/share CAGR 1.25-1.5x ON's 187.70%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
93.61%
3Y net income/share CAGR 50-75% of ON's 157.96%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
91.65%
Equity/share CAGR of 91.65% while ON is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
10.40%
Below 50% of ON's 101.36%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-4.05%
Negative 3Y equity/share growth while ON is at 102.43%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
361.20%
Dividend/share CAGR of 361.20% while ON is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
355.42%
Dividend/share CAGR of 355.42% while ON is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
294.10%
3Y dividend/share CAGR above 1.5x ON's 60.58%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
-13.89%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-2.21%
Inventory is declining while ON stands at 1.85%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-7.70%
Negative asset growth while ON invests at 7.29%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-7.50%
We have a declining book value while ON shows 192.87%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-6.09%
Our R&D shrinks while ON invests at 2.91%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.63%
We cut SG&A while ON invests at 0.22%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.